Bioenergy strength not very convincing
28/01/20 -"Novozymes reported mixed Q4 19 numbers – missing on topline but beating bottomline estimates. Sales came in at DKK 3,731m, up 1% on an organic basis, led by growth in Household. EBIT came in at DKK ..."
Pages
51
Language
English
Published on
28/01/20
You may also be interested by these reports :
17/04/24
Q1 sales exceeded expectations, driven by a strong performance from the Companion Animal segment. The Farm Animal segment was however held back by a ...
16/04/24
Preview: Positive 1Q24 driven by clinical developments of portfolio companies
15/04/24
Investor appetite for Merck KGaA (Add, Germany) shares has been somewhat subdued since we last teased the name (15/03/2021). At that time, the ...
15/04/24
Turnaround story on track – TP increased to CHF 30.00 (from CHF 25.00) – Add reiterated